Abiopharma

MCEWEN INC. (MUX) Reports the reporting period Financial Results MCEWEN INC. (MUX) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 77871
• Net Income: 33205
• EPS: Not disclosed
• Cash and equivalents: $74
  • targeting combined annual production from Grey Fox and Stock of 75,000 - 90,000 GEOs by 2030
  • expected by early 2027
  • anticipated in such statements and information. Risks and uncertainties that could cause results or future events to differ materially from current expectations expressed or implied by the forward-looking statements and information include, but are not limited to, fluctuations in the market price of precious metals, mining industry risks, political, economic, social and security risks associated with foreign operations, the ability of the Company to receive or receive in a timely manner permits or other approvals required in connection with operations, risks associated with the construction of mining operations and commencement of production and the projected costs thereof, risks related to litigation, the state of the capital markets, environmental risks and hazards, uncertainty as to calculation of mineral resources and reserves, foreign exchange volatility, foreign exchange controls, foreign currency risk, and other risks. Readers should not place undue reliance on forward-looking statements or information included herein, which speak only as of the date hereof. The Company undertakes no obligation to reissue or update forward-looking statements or information as a result of new information or events after the date hereof except as may be required by law. See McEwen Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025